Inrebic and Omacetaxine

In the database of official manuals used in the service creation an interaction registered by statistical results of studies was found, which can either lead to negative consequences for the patient health or strengthen a mutual positive effect. A doctor should be consulted to address the issue of joint drug administration.

Consumer information for this interaction is not currently available.GENERALLY AVOID: Coadministration of omacetaxine and drugs that interfere with platelet function or coagulation may potentiate the risk of bleeding complications. Treatment with omacetaxine is associated with a high frequency of thrombocytopenia. In one study, the overall incidence of grade 3 and 4 thrombocytopenia was 85% and 88%. Fatal cerebral hemorrhages occurred in 2% of patients receiving omacetaxine and nonfatal gastrointestinal hemorrhages occurred in 2%. MANAGEMENT: Concomitant use of other medications that interfere with platelet function or coagulation should be avoided if the patient's platelet count is less than 50,000 per microliter. Close clinical and laboratory observation for bleeding complications is recommended during therapy. The CBC and platelet count should be monitored according to the manufacturer's recommendations. Patients should be advised to immediately report signs of hemorrhage including unusual bleeding, bruising, blood in the urine or feces, confusion, blurry vision, or slurred speech. References "Product Information. Synribo (omacetaxine)." Teva Pharmaceuticals USA, North Wales, PA.

GENERALLY AVOID: Coadministration of omacetaxine and drugs that interfere with platelet function or coagulation may potentiate the risk of bleeding complications. Treatment with omacetaxine is associated with a high frequency of thrombocytopenia. In one study, the overall incidence of grade 3 and 4 thrombocytopenia was 85% and 88%. Fatal cerebral hemorrhages occurred in 2% of patients receiving omacetaxine and nonfatal gastrointestinal hemorrhages occurred in 2%.

MANAGEMENT: Concomitant use of other medications that interfere with platelet function or coagulation should be avoided if the patient's platelet count is less than 50,000 per microliter. Close clinical and laboratory observation for bleeding complications is recommended during therapy. The CBC and platelet count should be monitored according to the manufacturer's recommendations. Patients should be advised to immediately report signs of hemorrhage including unusual bleeding, bruising, blood in the urine or feces, confusion, blurry vision, or slurred speech.

Inrebic

Generic Name: fedratinib

Brand name: Inrebic

Synonyms: n.a.

What is Inrebic?

Omacetaxine

Generic Name: omacetaxine

Brand name: Synribo

Synonyms: Omacetaxine Mepesuccinate

What is Omacetaxine?